{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T08:23:33Z","timestamp":1794299013375,"version":"4.9.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"11","funder":[{"name":"National Cancer Institute and American Cancer Society","id":[{"id":"https:\/\/ror.org\/02e463172","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Advances in cancer treatment and increased survivorship have altered the economic burden of cancer care. Updated patient-level estimates of cancer-attributable costs, based on clinical and socioeconomic factors, are required.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data, we identified individuals aged \u226566\u2009years who were diagnosed with cancer during 2008-2019 and matched controls without a cancer history based on demographic characteristics, comorbidity burden, and area-level socioeconomic status. Cancer-attributable costs were estimated for 2013-2019 according to cancer site, stage, age, sex, race, and calendar year. Phases of care were defined as initial (first 12\u2009months after diagnosis), continuing, and end-of-life (EOL; final 12\u2009months before death from cancer). Net annualized cancer-attributable costs were calculated as the difference between cases and matched controls and are reported in USD 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Net annualized cancer-attributable medical service costs were highest in the EOL phase ($121\u00a0746), followed by the initial ($45\u00a0063), and continuing ($7141) phases. Oral prescription drug costs increased over time across all phases, particularly in EOL (from $4823 in 2013 to $11\u00a0620 in 2019), whereas medical service and hospitalization costs remained relatively stable after adjustment for inflation. Acute leukemia and distant-stage cancers incurred the highest cost. Cancer-attributable costs were higher among Black individuals and individuals of other races than among White individuals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion(s)<\/jats:title>\n                    <jats:p>Cancer-attributable costs vary substantially according to the care phase, cancer type, stage at diagnosis, and race. Rising costs, particularly for EOL care and prescription drugs, highlight the importance of aligning treatment intensity with patient goals and providing critical inputs for simulation and cost-effectiveness analyses of cancer-control interventions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jnci\/djag200","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:50:26Z","timestamp":1782301826000},"page":"2145-2158","source":"Crossref","is-referenced-by-count":2,"title":["Cancer-attributable costs in older adults: SEER-Medicare analysis of variation by site, stage, and race"],"prefix":"10.1093","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2423-1834","authenticated-orcid":false,"given":"Angela B","family":"Mariotto","sequence":"first","affiliation":[{"name":"Division of Cancer Control and Population Sciences, National Cancer Institute , Bethesda, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0452-5771","authenticated-orcid":false,"given":"Lindsey","family":"Enewold","sequence":"additional","affiliation":[{"name":"Division of Cancer Control and Population Sciences, National Cancer Institute , Bethesda, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A","family":"Zeruto","sequence":"additional","affiliation":[{"name":"Information Management Services, Inc. , Calverton, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9548-5770","authenticated-orcid":false,"given":"Yoon Duk","family":"Hong","sequence":"additional","affiliation":[{"name":"Division of Cancer Control and Population Sciences, National Cancer Institute , Bethesda, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0635-219X","authenticated-orcid":false,"given":"Douglas R","family":"Lowy","sequence":"additional","affiliation":[{"name":"National Cancer Institute Center for Cancer Research, , Bethesda, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0644-5572","authenticated-orcid":false,"given":"K Robin","family":"Yabroff","sequence":"additional","affiliation":[{"name":"Surveillance, Prevention & Health Services Research, American Cancer Society , Atlanta, GA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"2026111002540222200_djag200-B1","first-page":"308","article-title":"Cancer treatment and survivorship statistics, 2025","volume":"75","author":"Wagle","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"2026111002540222200_djag200-B2","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1093\/jnci\/djac141","article-title":"Costs around the first year of diagnosis for 4 common cancers among the privately insured","volume":"114","author":"Shih","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"2026111002540222200_djag200-B3","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jgo.2020.11.007","article-title":"Rapid rise in the cost of targeted cancer therapies for Medicare patients with solid tumors from 2006 to 2015","volume":"12","author":"Wilson","year":"2021","journal-title":"J Geriatr Oncol"},{"key":"2026111002540222200_djag200-B4","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1200\/JCO.2017.72.3742","article-title":"Rising prices of targeted oral anticancer medications and associated financial burden on Medicare beneficiaries","volume":"35","author":"Shih","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026111002540222200_djag200-B5","doi-asserted-by":"crossref","first-page":"e2221468","DOI":"10.1001\/jamanetworkopen.2022.21468","article-title":"Evaluation of trends in oncology drug spending in Medicare, 2016 to 2020","volume":"5","author":"Kyle","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026111002540222200_djag200-B6","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1158\/1055-9965.EPI-19-1534","article-title":"Medical care costs associated with cancer survivorship in the United States","volume":"29","author":"Mariotto","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2026111002540222200_djag200-B7","year":"2025"},{"key":"2026111002540222200_djag200-B8"},{"key":"2026111002540222200_djag200-B9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jnci\/djq495","article-title":"Projections of the cost of cancer care in the United States: 2010-2020","volume":"103","author":"Mariotto","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"2026111002540222200_djag200-B10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/jncimonographs\/lgz032","article-title":"Cancer-attributable medical costs for colorectal cancer patients by phases of care: what is the effect of a prior cancer history?","volume":"2020","author":"Mariotto","year":"2020","journal-title":"J Natl Cancer Inst Monogr"},{"key":"2026111002540222200_djag200-B11","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/jnci\/djn103","article-title":"Cost of care for elderly cancer patients in the United States","volume":"100","author":"Yabroff","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"2026111002540222200_djag200-B12","first-page":"3","article-title":"Updated overview of the SEER-Medicare data: enhanced content and applications","volume":"2020","author":"Enewold","year":"2020","journal-title":"J Natl Cancer Inst Monogr"},{"key":"2026111002540222200_djag200-B13","year":"2025"},{"key":"2026111002540222200_djag200-B14"},{"key":"2026111002540222200_djag200-B15","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.annepidem.2007.03.011","article-title":"A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients","volume":"17","author":"Klabunde","year":"2007","journal-title":"Ann Epidemiol"},{"key":"2026111002540222200_djag200-B16"},{"key":"2026111002540222200_djag200-B17","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1200\/JCO.2016.71.9716","article-title":"Economic burden of chronic conditions among survivors of cancer in the United States","volume":"35","author":"Guy","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026111002540222200_djag200-B18"},{"key":"2026111002540222200_djag200-B19","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1200\/JCO.2015.61.6706","article-title":"American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options","volume":"33","author":"Schnipper","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026111002540222200_djag200-B20","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1200\/JCO.2016.68.2518","article-title":"Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received","volume":"34","author":"Schnipper","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026111002540222200_djag200-B21","doi-asserted-by":"crossref","first-page":"e35976","DOI":"10.1002\/cncr.35976","article-title":"Patient-reported discordance between care goals and treatment intent in advanced cancer","volume":"131","author":"Shah","year":"2025","journal-title":"Cancer"},{"key":"2026111002540222200_djag200-B22","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/COC.0000000000000485","article-title":"Factors affecting racial disparities in end-of-life care costs among lung cancer patients: a SEER-Medicare-based study","volume":"42","author":"Karanth","year":"2019","journal-title":"Am J Clin Oncol"},{"key":"2026111002540222200_djag200-B23","doi-asserted-by":"crossref","first-page":"S236","DOI":"10.1016\/j.jval.2023.03.2618","article-title":"Comparisons of medical cost trajectories between non-Hispanic Black and non-Hispanic White patients with newly diagnosed localized prostate cancer","volume":"26","author":"Liu","year":"2023","journal-title":"Value Health"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djag200\/70160792\/djag200.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/11\/2145\/70160792\/djag200.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/11\/2145\/70160792\/djag200.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T07:54:09Z","timestamp":1794297249000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/118\/11\/2145\/8742267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":23,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,7,28]]},"published-print":{"date-parts":[[2026,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djag200","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,7,28]]}}}